Novavax (NVAX) Convertible Debt (2016 - 2025)
Historic Convertible Debt for Novavax (NVAX) over the last 10 years, with Q3 2025 value amounting to $243.8 million.
- Novavax's Convertible Debt rose 4405.52% to $243.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $243.8 million, marking a year-over-year increase of 4405.52%. This contributed to the annual value of $169.7 million for FY2024, which is 99.28% up from last year.
- According to the latest figures from Q3 2025, Novavax's Convertible Debt is $243.8 million, which was up 4405.52% from $170.6 million recorded in Q2 2025.
- Novavax's 5-year Convertible Debt high stood at $324.5 million for Q3 2022, and its period low was $166.5 million during Q4 2022.
- Its 5-year average for Convertible Debt is $229.5 million, with a median of $170.1 million in 2025.
- In the last 5 years, Novavax's Convertible Debt tumbled by 4853.55% in 2022 and then surged by 4405.52% in 2025.
- Over the past 5 years, Novavax's Convertible Debt (Quarter) stood at $323.5 million in 2021, then tumbled by 48.54% to $166.5 million in 2022, then grew by 0.93% to $168.0 million in 2023, then increased by 0.99% to $169.7 million in 2024, then skyrocketed by 43.7% to $243.8 million in 2025.
- Its Convertible Debt stands at $243.8 million for Q3 2025, versus $170.6 million for Q2 2025 and $170.1 million for Q1 2025.